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The BN is guarded against overfitting using k-fold cross 
validation. 
Results:  BNs representing the biophysical relationships 
before and during the course of radiotherapy behind the 
radiation outcomes are identified and designated as 
“biophysical BNs’’.  They can be adjusted to “practical BNs” 
for adaptive therapy purposes, with a possibility of minor 
compromise of estimated prediction power.  Given a 
patient’s pretreatment data, an appropriate treatment plan 
can be chosen from a practical BN to control the tumor and 
keep the radiation toxicities under a certain level.  When the 
patient’s during treatment information is available, the 
planned dose can be adjusted in the BN according to his/her 
responses, to better control tumor without increasing the 
chance of the complication.  Cross validation is employed to 
measure the prediction power of the BNs.  For example, 
while the performance of a pretreatment BN to predict 
radiation pneumonitis ≥G2 is 0.80 with 95% CI: 0.69-0.90 
based on 2000 stratified bootstrap replicates, the AUC of the 
BN with patients’ responses during radiotherapy can reach 
0.84 (95% CI: 0.78-0.92). 
Conclusions:  We developed clinically practical systems to 
predict the radiation outcomes in NSCLC patients before and 
during the course of radiation treatment based on 
retrospective data.  The prediction performance of the BN 
improves by incorporating during treatment information.  Our 
approach can handle high dimensional predictors and can be 
an important component of decision support for personalized 
adaptive radiation treatment.  However, it still needs to be 
validated in external independent data. 
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Purpose: The interest in particle therapy is growing 
worldwide with clinical applications focused on protons and 
carbon ion beams. Moreover, at the Heidelberg Ion Beam 
Therapy Center, helium and oxygen ions are available for 
research purposes with an active scanning beam delivery 
system. While most of the planning studies comparing these 
four ions are based on non-experimentally validated 
calculations, this work is focused on the basic experimental 
dosimetric characterizations and comparisons of these ions at 
the same facility. 
Material/methods: Laterally integrated depth-dose 
distributions of pencil-like beams, for 10 different energies in 
the therapeutic range have been experimentally studied, 
with a range in water similar for every ion. Several 
parameters were evaluated, as the range, the entrance-to-
peak ratio, the width of the Bragg peak, the distal fall-off 
and the tail-to-peak ratio, and this with and without ripple 
filter (used to broaden the pristine peaks). The 
measurements were performed using a water column, by 
delivering quasi-monoenergetic pencil-like beams on the 
central axis. 
The lateral dose profiles of these ions, at low, middle and 
high beam energy, were investigated at different depths in 
water (without ripple filter). Along with the acquisition of 
these data, a double-Gaussian parametrization was 
performed and the evolution of its components along the 
depth in water was examined. The measurements have been 
done in a water tank coupled with 24 motor-driven PinPoint 
ionization chambers by delivering a vertically scanned beam. 
Results: For the depth-dose characterization, the evolution 
of the investigated parameters presents a different behavior 
depending on the energy, the ion and the presence or not of 
ripple filter. Helium ions present interesting intermediate 
characteristics with a distal fall-off smaller than protons and 
a reduce fragmentation tail compare to heavier ions. These 
characteristics suggest different advantages and/or 
drawbacks for the ions depending on the situation, and a 
compromise among them has to be found for later treatment 
planning. 
The lateral profiles and their double Gaussian 
parametrizations present net advantages of the heavy ions 
compared to protons with intermediate results for helium 
ions. 
Conclusions: Our experimental results indicate that helium 
ions could be a good candidate for further particle therapy 
improvements, with intermediate properties between the 
clinically used proton and carbon ions. The main features are 
the favorable physical characteristics, especially a smaller 
lateral scattering than protons and a very low tail-to-peak 
ratio compared to carbon ions. This study was used to create 
the first helium ions database, allowing biological 
experiments needed to ensure proper treatment planning and 
future fair comparisons for planning studies between the 
ions. 
We acknowledge funding from DFG (KFO 
Schwerionentherapie 214). 
 
 
Figure 1: Measured Bragg peaks (symbols) and their 
interpolation (lines), normalized to maximum and to the 
peak position, for a range in water of ~15cm.  
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Over the last decades, survival rates for most cancer patients 
have only marginally increased. One reason for the limited 
decline in this death rate is the lack of effective treatment 
strategies especially in advanced cancers. In oncology 
research, drug development processes have proven to be very 
inefficient and this has been partly attributed to the lack of 
adequate preclinical testing modalities. Research in our lab is 
specifically focused on lung and brain cancer, both amongst 
the most malignant and difficult to treat neoplasms with very 
poor overall 5-year survival rates. In advanced disease most 
patients receive chemo- and radiotherapy (CRT), but 
response to treatment is generally poor with only minimal 
effects on survival while decreasing the patients’ quality of 
life. Tumors almost invariably recur or are intrinsically 
resistant to chemotherapy. Improvement of tumor control at 
primary and distant locations is compulsory. The goal of our 
research is to identify novel treatment combinations that will 
result in improved outcome for patients with advanced lung 
or brain malignancies. 
